Dicerna Pharma (DRNA) Misses Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts DRNA Hot Sheet
Join SI Premium – FREE
Dicerna Pharma (NASDAQ: DRNA) reported Q3 EPS of ($0.92), $0.23 worse than the analyst estimate of ($0.69).
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Highlights Top Shopping Center REITs Ahead of Q3 Earnings
- New Street bullish on Intel to Buy as CPU scarcity strengthens turnaround
- CVR Energy stock climbs ahead of earnings report
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
